Germany - "Open framework agreement on drug discounts pursuant to Section 130a (8) sentence 1 SGB V with the possibility of joining at any time, so-called approval model 2019-6".

Description

The purpose of this announcement is to conclude agreements with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code (Sozialgesetzbuch, SGB V) (discount agreements). Pursuant to § 130a para. 8 sentence 1 SGB V, the invitation to participate is only addressed to pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of § 4 para. 18 Arzneimittelgesetz (AMG). It is not an open procedure, but a publication of the invitation to conclude/join/rebate agreements with fixed and non-negotiable conditions for all participants, including the amount of the rebate. An unlimited number of pharmaceutical entrepreneurs or employee associations of pharmaceutical entrepreneurs within the meaning of Section 4 (18) of the German Medicines Act (Arzneimittelgesetz - AMG) may become contractual partners. The conclusion or accession of a contract shall be effected by completing the required self-declarations or supporting documents and the contract(s) either
a) handwritten signed (written form according to § 126 BGB) by mail or
b) provided with a qualified electronic signature (§ 126a BGB) be sent by e-mail to openhouse.rabattvertrag2019-6@kbs.de to the KBS.
The earliest commencement date of the contract is 01.11.2019, provided that the contract and the required declarations or proofs have been received by the KBS by 05.10.2019 at the latest. The start of the contract is thus the 1st of the month following the month of receipt of the contract as well as the required declarations or proofs by the KBS, provided that receipt takes place by the 5th of each month; otherwise the 1st of the month after next. The contracts shall end automatically, without any notice of termination being required, as soon as the contractual partner(s) for the active substance(s) or combination(s) of active substances has/have been determined by way of a formal award procedure. The deadline for the receipt of accessions is 05.09.2021. In any case, the contracts expire on 31.10.2021.
In detail, contracts may be concluded for the following active substances/drug combinations
The link to the order documents can be requested by e-mail (openhouse.rabattvertrag2019-6@kbs.de). The documents will be made available on the homepage of the KBS.

Opportunity closing date

05 September 2021

Value of contract

to be confirmed